SGS Announces Release of New Influenza Strain
The company made a new strain of the influenza virus available for use as a challenge agent in clinical trials.
SGS made a new strain of the influenza virus available for use as a challenge agent in clinical trials on Jan. 10, 2017. The synthetic virus may be used to test the efficacy of both novel influenza drugs and vaccines in healthy volunteers.
The new agent is a H3N2-type virus, which represents one of the common current circulating strains of influenza of a pandemic origin. Its manufacture has been undertaken by SGS in accordance with good manufacturing practice to ensure that strict FDA and European Medicines Agency regulatory guidelines are met. The virus is currently undergoing an array of both adventitious and purity tests. It is anticipated that final safety and activity data from the first-in-human studies using the virus will be announced in a presentation at the World Vaccine Congress, to be held in Washington DC, in April 2017.
The company has a containment-Level 2, 20-bed human challenge unit providing full isolation capabilities and offering services for challenge trials performed with the new influenza agent. The unit is located in Antwerp’s Stuivenberg Hospital, Belgium.
Source: SGS
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
